US equities
|
NVDA
$204.64
▼-4.22%
INTC
$65.76
▼-28.58%
MU
$884.74
▼-5.30%
AMZN
$240.35
▼-1.41%
AAPL
$344.63
▼-1.23%
SNDK
$1,150.89
▼-13.47%
AMD
$504.80
▼-10.88%
MSFT
$521.91
▼-1.55%
NVDA
$204.64
▼-4.22%
INTC
$65.76
▼-28.58%
MU
$884.74
▼-5.30%
AMZN
$240.35
▼-1.41%
AAPL
$344.63
▼-1.23%
SNDK
$1,150.89
▼-13.47%
AMD
$504.80
▼-10.88%
MSFT
$521.91
▼-1.55%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Tools
My watchlist
My portfolio
Recent quotes
Ligand Pharmaceuticals Incorporated - Common Stock
(NQ:
LGND
)
322.75
+5.42 (+1.71%)
Delayed Quote
Updated: 4:00 PM EDT, Oct 30, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Ligand Pharmaceuticals Incorporated - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
Next >
Ligand (LGND) Q3 2026 Earnings Call Transcript
↗
October 30, 2026
Royalty revenue surged 51% on XOMA acquisition and Filspari momentum.
Via
The Motley Fool
Topics
Earnings
What Ligand Pharmaceuticals (LGND) Said on Its Q3 Earnings Call
↗
October 29, 2026
Ligand Pharmaceuticals (NASDAQ:LGND) reported third-quarter royalty revenue growth of 51% year over year to approximately $70 million, driven by Filspari, Ohtuvayre and commercial assets acquired...
Via
MarketBeat
Topics
Earnings
Ligand Pharmaceuticals (NASDAQ:LGND) Flashes Strong Trend and High-Growth Momentum Despite Setup Caution
↗
September 28, 2026
Via
Chartmill
If You Invested $100 In Ligand Pharmaceuticals Stock 5 Years Ago, You Would Have This Much Today
↗
September 02, 2026
Ligand Pharmaceuticals (NASDAQ:LGND) has outperformed the market over the past 5 years by 17.28% on an annualized basis producing an average annual return of 28.4%. Currently, Ligand Pharmaceuticals...
Via
Benzinga
Ligand Pharmaceuticals (NASDAQ:LGND) Beats Q2 EPS Estimates, Shares Flat on In-Line Revenue
↗
August 06, 2026
Via
Chartmill
Ligand Pharmaceuticals (NASDAQ:LGND) Shares Fall on Q1 Revenue and EPS Miss
↗
May 07, 2026
Via
Chartmill
Ligand Pharmaceuticals (NASDAQ:LGND) Passes Minervini Trend Template and Growth Screen
↗
April 01, 2026
Via
Chartmill
Ligand Pharmaceuticals Highlights XOMA-Fueled Royalty Growth, $700M in Deployable Capital
↗
August 26, 2026
Ligand Pharmaceuticals (NASDAQ:LGND) outlined its royalty-focused growth strategy, recent XOMA acquisition and portfolio catalysts during a company presentation, highlighting a larger commercial-stage...
Via
MarketBeat
$100 Invested In Ligand Pharmaceuticals 10 Years Ago Would Be Worth This Much Today
↗
August 21, 2026
Ligand Pharmaceuticals (NASDAQ:LGND) has outperformed the market over the past 10 years by 2.79% on an annualized basis producing an average annual return of 16.18%. Currently, Ligand Pharmaceuticals...
Via
Benzinga
Ligand (LGND) Q2 2026 Earnings Call Transcript
↗
August 13, 2026
XOMA acquisition and convertible financing boost 2026 guidance to $9.00–$9.50 per share.
Via
The Motley Fool
Topics
Earnings
Ligand Pharmaceuticals Q2 Earnings Call Highlights
↗
August 06, 2026
Ligand Pharmaceuticals (NASDAQ:LGND) reported second-quarter 2026 results marked by higher royalty revenue and adjusted earnings, while highlighting the post-quarter close of its XOMA Royalty...
Via
MarketBeat
Topics
Earnings
$100 Invested In Ligand Pharmaceuticals 15 Years Ago Would Be Worth This Much Today
↗
August 05, 2026
Ligand Pharmaceuticals (NASDAQ:LGND) has outperformed the market over the past 15 years by 14.91% on an annualized basis producing an average annual return of 28.27%. Currently, Ligand Pharmaceuticals...
Via
Benzinga
Ligand Completes Acquisition of XOMA Royalty, Creating a Portfolio of More than 200 Biopharmaceutical Royalty Assets
July 14, 2026
From
Ligand Pharmaceuticals
Via
GlobeNewswire
XOMA Royalty Announces Closing of Its Acquisition by Ligand
July 14, 2026
From
XOMA Royalty Corporation
Via
GlobeNewswire
3 Overlooked Stocks Positioned for the Next Market Rotation
↗
July 13, 2026
Oxford Club strategist Marc Lichtenfeld highlights diversification beyond tech, spotlighting Ligand Pharmaceuticals, Aflac and Atlantic Union Bankshares as healthcare, insurance and banking stocks...
Via
MarketBeat
Topics
Artificial Intelligence
Ligand Pharmaceuticals Director Unloads 2,501 Shares — Should You Be Concerned?
↗
June 14, 2026
This biotech innovator, known for its royalty-driven model, reported a notable insider sale amid a period of strong share price gains.
Via
The Motley Fool
Topics
Regulatory Compliance
A Ligand Pharmaceuticals (LGND) Insider Sold 5,000 Shares for $1.1 Million
↗
June 07, 2026
Biotech royalty player Ligand Pharmaceuticals reported a notable insider sale following a year of strong stock performance.
Via
The Motley Fool
Topics
Regulatory Compliance
Wealth Manager Sells $7 Million of Establishment Labs After Massive Gains. Is This Medical Device Stock a Buy?
↗
May 30, 2026
Establishment Labs develops advanced silicone implants and medical devices for global plastic surgery markets.
Via
The Motley Fool
Topics
Regulatory Compliance
OneSpaWorld Posted Record Revenue for Last Quarter. Why Did a Fund Exit a $21.5 Million Stake?
↗
May 29, 2026
OneSpaWorld provides spa, fitness, and beauty services to cruise and resort guests through exclusive wellness partnerships worldwide.
Via
The Motley Fool
Topics
Regulatory Compliance
Is Genpact Stock a Buy After Hedge Fund Rice Hall James Raised Its Stake by $14 Million?
↗
May 19, 2026
Genpact delivers business process and IT services to global enterprises, with a diversified client base across multiple industries.
Via
The Motley Fool
Topics
Artificial Intelligence
Economy
Is WaterBridge Stock a Buy After Ranger Investment Raised Its Stake by 345,000 Shares?
↗
May 16, 2026
WaterBridge Infrastructure delivers water management and recycling services to oil and gas producers across major U.S. shale basins.
Via
The Motley Fool
Topics
Initial Public Offering
Orchestra BioMed Reports First Quarter 2026 Financial Results and Highlights Recent Business Updates
May 12, 2026
From
Orchestra BioMed Holdings, Inc.
Via
GlobeNewswire
Ligand (LGND) Q1 2026 Earnings Call Transcript
↗
May 12, 2026
Ligand (LGND) Q1 2026 Earnings Call Transcript
Via
The Motley Fool
Topics
Earnings
Ligand Pharmaceuticals Q1 Earnings Call Highlights
↗
May 08, 2026
Ligand Pharmaceuticals (NASDAQ:LGND) reported first-quarter 2026 results that management said reflect the operating leverage of its royalty aggregation strategy, highlighted by growing royalties from...
Via
MarketBeat
Topics
Earnings
Orchestra BioMed Receives $15 Million Investment from Ligand Under Previously Announced Strategic Financing Agreement
May 06, 2026
From
Orchestra BioMed Holdings, Inc.
Via
GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: XOMA Royalty Corporation (Nasdaq – XOMA), Organon & Co. (NYSE – OGN), RE/MAX Holdings, Inc. (NYSE – RMAX), Soleno Therapeutics, Inc. (Nasdaq – SLNO)
May 05, 2026
From
Brodsky & Smith LLC
Via
GlobeNewswire
Villere St Denis Liquidates $18 Million Euronet Worldwide Stake, According to Recent SEC Filing
↗
May 04, 2026
Euronet Worldwide encompasses ATM and electronic funds transfer (EFT) services, prepaid distribution, and money transfer, resulting in a more complex structure than that of a typical payments network....
Via
The Motley Fool
Topics
Regulatory Compliance
Villere St Denis Dumps 134,000 Tidewater (TDW) Shares Worth $9.3 Million
↗
May 02, 2026
Specializing in offshore marine support, Tidewater serves global energy clients across oil, gas, and windfarm projects.
Via
The Motley Fool
Topics
Energy
Regulatory Compliance
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: XOMA Royalty Corporation (Nasdaq – XOMA), Organon & Co. (NYSE – OGN), RE/MAX Holdings, Inc. (NYSE – RMAX), Soleno Therapeutics, Inc. (Nasdaq – SLNO)
April 27, 2026
From
Brodsky & Smith LLC
Via
GlobeNewswire
Ligand to Acquire XOMA Royalty, Further Accelerating Profit Growth and Strengthening Ligand’s Position as a Leading Biopharma Royalty Aggregator
April 27, 2026
From
XOMA Royalty Corporation
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
Next >
